These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6475941)

  • 1. Spontaneous disappearance of an IgA anti-factor IX inhibitor in a child with Christmas disease.
    Carroll RR; Panush RS; Kitchens CS
    Am J Hematol; 1984 Oct; 17(3):321-5. PubMed ID: 6475941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on Christmas disease: investigation and treatment of a familial acquired inhibitor of factor IX.
    George JN; Miller GM; Breckenridge RT
    Br J Haematol; 1971 Sep; 21(3):333-42. PubMed ID: 4998792
    [No Abstract]   [Full Text] [Related]  

  • 3. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.
    Boylan B; Rice AS; Neff AT; Manco-Johnson MJ; Kempton CL; Miller CH;
    J Thromb Haemost; 2016 Oct; 14(10):1931-1940. PubMed ID: 27501440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG subclass identification of inhibitors to factor IX in haemophilia B patients.
    Orstavik KH; Miller CH
    Br J Haematol; 1988 Apr; 68(4):451-4. PubMed ID: 3377985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of an occult inhibitor to factor IX in a haemophilia B patient.
    Miller CH; Orstavik KH; Hilgartner MW
    Br J Haematol; 1985 Oct; 61(2):329-38. PubMed ID: 4041376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate.
    Giddings JC; Bloom AL; Kelly MA; Spratt HC
    Clin Lab Haematol; 1983; 5(2):165-75. PubMed ID: 6603957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced tolerance in hemophilia patients with antibodies against IX:C.
    Hedner U; Nilsson IM
    Acta Med Scand; 1983; 214(3):191-7. PubMed ID: 6660025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
    Orstavik KH
    Thromb Haemost; 1981 Dec; 46(4):684-6. PubMed ID: 7330818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient.
    Verghese P; Darrow S; Kurth MH; Reed RC; Kim Y; Kearney S
    Pediatr Nephrol; 2013 May; 28(5):823-6. PubMed ID: 23381011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of immunosuppression in a severe haemophilia B patient with specific antibody.
    Allain JP; Frommel D
    Thromb Haemost; 1976 Aug; 36(1):86-9. PubMed ID: 1036830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.
    Nilsson IM; Berntorp E; Zettervall O
    Proc Natl Acad Sci U S A; 1986 Dec; 83(23):9169-73. PubMed ID: 3491368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with hemophilia B (Christmas disease) who have anti-factor IX: genetic heterogeneity.
    Poon MC
    J Lab Clin Med; 1988 Sep; 112(3):283-4. PubMed ID: 3411190
    [No Abstract]   [Full Text] [Related]  

  • 16. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.
    Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL
    Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disappearance of inhibitor to factor IX in a patient with severe haemophilia B and immunological characterization of the inhibitor.
    Ohkubo Y; Takahashi Y; Sugimoto M; Nishino M; Nishimura T; Yoshioka A; Fukui H
    Clin Lab Haematol; 1988; 10(2):177-85. PubMed ID: 2843318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B.
    Tomokiyo K; Teshima K; Nakatomi Y; Watanabe T; Mizuguchi J; Nozaki C; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Thromb Res; 2001 May; 102(4):363-74. PubMed ID: 11369429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of factor IX inhibitors by immunoradiometric assay.
    Ljung R; Holmberg L
    Acta Haematol; 1983; 70(5):307-11. PubMed ID: 6414224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors in congenital coagulation disorders.
    Key NS
    Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.